DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu

DIOSynVax Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom Australia China Japan Malaysia South Korea Thailand New York

 

or contact:
Email: [e-mail] 
Website: Advisory Board | DIOSynVax

About COVID-19
For more information about COVID-19, visit the CDC website.

About H5N1 (Bird Flu)
H5N1, or bird flu, continues to pose a significant threat to public health, particularly if the virus undergoes mutations that enable transmission among humans. For further details, visit the CDC H5N1 situation summary.

 

View original content:https://www.prnewswire.co.uk/news-releases/diosynvax-announces-a-new-advisory-board-as-it-drives-the-clinical-development-of-its-nextgen-influenza-vaccines-including-bird-flu-302346249.html